Is Amicus Therapeutics, Inc. overvalued or undervalued?

As of 7 November 2016, the valuation grade for Amicus Therapeutics, Inc. moved from does not qualify to risky, indicating a heightened level of uncertainty regarding its financial health. The company appears to be overvalued, as evidenced by its Price to Book Value of 9.80 and an EV to EBITDA ratio of 36.52, which are significantly higher than many of its peers. In comparison, Alkermes Plc, which is rated attractive, has a much lower EV to EBITDA of 9.4080, while Ionis Pharmaceuticals, Inc. also shows a risky valuation with an EV to EBITDA of -37.8563.
The stock has experienced mixed performance, with a one-week return of 5.74% compared to the S&P 500's 1.05%, but it has significantly underperformed over longer periods, including a year-to-date return of -9.98% versus the S&P 500's 12.22%. This trend reinforces the notion that Amicus Therapeutics, Inc. is overvalued relative to its peers and the broader market.